An underground market for unlicensed weight-loss drugs is being driven by social media fitness personalities and sellers on messaging platforms, based on recent findings.
Investigational Drug Gaining Popularity Online
The experimental drug, which is still in research studies, is being advertised by social media influencers for its alleged fat-burning properties. Followers are encouraged to message these accounts directly for supplier links, while also obtaining promotional offers.
Thriving Commerce on Messaging Platforms
Separately, a robust trade exists on messaging services, where communities with thousands of participants share comparison images, administration instructions and assertions of rapid British shipping. Sellers market the drug there before directing buyers to other platforms for purchases.
Learning About Retatrutide
Retatrutide is an experimental injection developed by American pharmaceutical company Eli Lilly. The drug affects three gut hormones – GLP-1, glucose-dependent insulinotropic polypeptide and pancreatic hormone. Early trials suggest it could assist individuals reduce up to a quarter of their total weight. Nicknamed the “triple G”, the drug is being hailed online as the successor to Ozempic.
Medical Professionals Express Concerns
However, doctors and chemists have warned that the sale of what remains an unlicensed medication in the UK is worrisome and could result in users administering products of uncertain source.
Some professionals stated the popularity for retatrutide could be linked to the increasing cost of licensed weight loss treatments such as Mounjaro.
Legal Position and Enforcement
Selling retatrutide on social media or Telegram is prohibited in the United Kingdom, as it is an unapproved medication that cannot be promoted or distributed for personal consumption under the Human Medicines Regulations 2012.
Some influencers attempt to circumvent the rules by referring to the substance as a “research chemical” or describing it as “not for human consumption”. Retatrutide is not a restricted substance, but promotion and distribution can still violate pharmaceutical, advertising, and customer laws, risking fines, prosecution or imprisonment.
Service Response and Content Removal
According to the social media company, the service has taken down violative content and prohibited associated hashtags and query recommendations. The company stated it was dedicated to maintaining the platform secure and allocating resources in strengthening enforcement strategies.
Digital Trading Operations
Investigations also found groups with up to 9,000 participants marketing retatrutide using the platform's built-in discovery tool, which operates like a public directory. Typing “retatrutide” immediately displays groups with numerous of users, populated with photos of weight loss, glowing reviews and detailed guides for mixing or administering at residence.
Within moments of entering one community, a vendor shared contact information, where the majority of purchases occur. The vendor provided an guidebook and promised delivery within two days. When questioned whether the substance was genuine, one seller said: “You can’t be sure.” Another shared a photo of a alleged testing documentation. Not one inquired about body mass, medical conditions or previous experience.
Product Details and Pricing
Within these communities, posts display black plastic parcels with Royal Mail stickers, stating to contain fresh supplies. One communication read: “It took eight of us to load them this morning.”
Buyers can choose between dry substance containers, mixed at residence with sterile water, or ready-to-use pens usually sold at 160 pounds for 20mg. When asked how much time a injector should be used, vendors give contradictory answers varying between a several days to “depends on your body”.
Service Moderation and Safety Measures
A spokesperson for the messaging service said it actively moderated dangerous content on its service including material that promoted the “misuse of controlled medications”. The company noted that it removed “millions of pieces of harmful content each day”.
Medical Professional Warnings
“Individuals are injecting materials they cannot confirm. Even if the science behind retatrutide is sound, these online products may not contain what they advertise,” stated a pharmacy expert, the head of pharmaceutical services at Chemist4U.
Dr Crystal Wyllie of Asda Online Doctor connected the surge in interest to current cost increases for authorized slimming drugs such as Mounjaro. “With costs increasing, individuals are using social media. But counterfeit treatments are highly dangerous. You cannot know what’s contained or whether the environment they were made in was sterile,” she explained.
Her staff has previously encountered patients harmed by self-injection from unverified suppliers. “We understand the frustration, but buying from Telegram or WhatsApp is gambling with your well-being,” stated Wyllie. “These materials could be impure or improperly measured.”
Producer Statement
A spokesperson from Eli Lilly stated the substance was in phase 3 research studies and had not been reviewed or authorized by any regulatory agency globally. “Therefore at this time no one can sell [it] for personal consumption,” they explained, noting that any product “misleadingly claiming itself as a Lilly investigational product not yet approved … may expose patients to possibly significant health risks”.
